Literature DB >> 2697528

Tissue localization of photosensitizers and the mechanism of photodynamic tissue destruction.

B W Henderson1, D A Bellnier.   

Abstract

This paper outlines our present knowledge of photosensitizer tissue distribution, derived from preclinical animal studies, and relates it to the observed biological response to photodynamic therapy (PDT). Emphasis is placed on porphyrins (haematoporphyrin derivative (HpD), Photofrin II) and phthalocyanines (aluminum phthalocyanine sulphonate AlPcS). In mice, both groups of sensitizers show multiphasic plasma clearance kinetics with an initial rapid decline followed by further slow reduction. Residual amounts of Photofrin II are detectable 75 days after injection. Drug elimination occurs through urine and faeces, but faecal elimination predominates for Photofrin II. Circulating sensitizer greatly influences the mouse ear-swelling response, but not the foot response. Tumours and normal skin can be destroyed by vascular damage, if illumination occurs at times of maximal plasma sensitizer concentration, with no detectable sensitizer accumulation in tumour cells. Organ retention for both photosensitizer groups is similar and persistent. Organs rich in reticuloendothelial elements (liver, kidney, spleen) accumulate and retain the highest levels, skin and muscle the lowest, while normal brain tissue excludes sensitizer. The adrenal and pancreatic glands, as well as urinary bladder, also retain high amounts of Photofrin II. Tumour/skin ratios of 1 to 3:1 and 2 to 7:1 have been reported for porphyrins and sulphonated phthalocyanines respectively. Tissue destruction upon light exposure is not always correlated with photosensitizer levels, as is exemplified by liver and pancreas. Stromal sensitizer localization usually predominates in tumour and normal tissue, and often determines tumour response. Certain compounds, such as monosulphonated tetraphenylporphyrin and AlPcS, may favour parenchymal localization. The formed blood elements remain free of photosensitizer, while mast cells and macrophages accumulate especially large amounts and, upon illumination, release an array of vasoactive inflammatory and immune mediators.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2697528     DOI: 10.1002/9780470513842.ch8

Source DB:  PubMed          Journal:  Ciba Found Symp        ISSN: 0300-5208


  13 in total

1.  Can nanotechnology potentiate photodynamic therapy?

Authors:  Ying-Ying Huang; Sulbha K Sharma; Tianhong Dai; Hoon Chung; Anastasia Yaroslavsky; Maria Garcia-Diaz; Julie Chang; Long Y Chiang; Michael R Hamblin
Journal:  Nanotechnol Rev       Date:  2012-03       Impact factor: 7.848

Review 2.  Photodynamic therapy: a review.

Authors:  J S McCaughan
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

3.  The impact of macrophage-cancer cell interaction on the efficacy of photodynamic therapy.

Authors:  Mladen Korbelik; Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2015-01-26       Impact factor: 3.982

4.  Adjuvant intraoperative photodynamic therapy in head and neck cancer.

Authors:  Nestor R Rigual; Gal Shafirstein; Jennifer Frustino; Mukund Seshadri; Michele Cooper; Gregory Wilding; Maureen A Sullivan; Barbara Henderson
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2013-07       Impact factor: 6.223

5.  Photodynamic therapy of early stage oral cavity and oropharynx neoplasms: an outcome analysis of 170 patients.

Authors:  Baris Karakullukcu; Kim van Oudenaarde; Marcel P Copper; W M C Klop; Robert van Veen; Maarten Wildeman; I Bing Tan
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-08-13       Impact factor: 2.503

6.  Evaluation of tumour and tissue distribution of porphyrins for use in photodynamic therapy.

Authors:  K W Woodburn; S Stylli; J S Hill; A H Kaye; J A Reiss; D R Phillips
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

7.  Tumour-localising and -photosensitising properties of a novel zinc(II) octadecylphthalocyanine.

Authors:  C Ometto; C Fabris; C Milanesi; G Jori; M J Cook; D A Russell
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

8.  Distribution of Photofrin between tumour cells and tumour associated macrophages.

Authors:  M Korbelik; G Krosl; P L Olive; D J Chaplin
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

9.  CGP 55398, a liposomal Ge(IV) phthalocyanine bearing two axially ligated cholesterol moieties: a new potential agent for photodynamic therapy of tumours.

Authors:  A Segalla; C Milanesi; G Jori; H G Capraro; U Isele; K Schieweck
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

10.  Interstitial photodynamic therapy in a rat liver metastasis model.

Authors:  R van Hillegersberg; J P Marijnissen; W J Kort; P E Zondervan; O T Terpstra; W M Star
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.